Clinical efficacy & future development of continuous glucose monitoring highlighted in DTT

0
IMAGE

Credit: Mary Ann Liebert, Inc., publishers

New Rochelle, NY, June 7, 2017–A growing body of data from clinical studies of continuous glucose monitoring (CGM) in type 1 diabetes supports the value of CGM for reducing variability in blood glucose levels and the risks of both hypo- and hyperglycemia, and for improving patient quality of life compared to self-monitoring of blood glucose (SMBG). A review of recent CGM trials and the impact of CGM accuracy on the future of automated insulin delivery systems are the focus of two in a series of articles published as a special supplement to Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The supplement is available open access on the DTT website.

In the article entitled "Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes," David Rodbard, MD, Biomedical Informatics Consultants, Potomac, MD, concluded that CGM, as well as flash glucose monitoring, has been shown to be safe and effective, with the recent regulatory approval of certain CGM devices for nonadjunctive use to guide insulin dose adjustment representing a major advance.

In the "Future of Automated Insulin Delivery Systems," Jessica Castle, MD, Oregon Health & Science University, Portland, J. Hans DeVries, MD, University of Amsterdam, The Netherlands, and Boris Kovatchev, PhD, University of Virginia, Charlottesville, discuss how CGM has enabled the automation of insulin delivery. The authors describe the rapid progress in the development of automated insulin delivery systems, the novel features and advantages they may offer for improving glycemic control, and the critical role that highly accurate CGM will play in the safe and effective use of these systems.

In the Editorial entitled "The Future of Continuous Glucose," DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora) states: "Continuous glucose monitors have come a long way with significant improvement in accuracy and MARD of

Research reported in this publication was supported by the National Institutes of Health under Award Number 1DP3DK101044-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

This supplement was supported by an educational grant from Dexcom. Dexcom G5 is the first and currently only CGM approved for nonadjunctive use in the US.

About the Journal

Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD

The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world's leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Media Contact

Kathryn Ryan
[email protected]
914-740-2250
@LiebertPub

http://www.liebertpub.com

Original Source

http://www.liebertpub.com/global/pressrelease/clinical-efficacy-and-future-development-of-continuous-glucose-monitoring-highlighted-in-dtt/2189/ http://dx.doi.org/10.1089/dia.2017.0035

############

Story Source: Materials provided by Scienmag

You might also like More from author

Leave A Reply

Your email address will not be published.

Join Our Newsletter Today 

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW